Back to mobile site

UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)

May 28, 2026 10:09 AM EDT Send to a Friend
UBS analyst Michael Yee reiterated a Buy rating and $70.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login